Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors

NCT04673942 is registered in ClinicalTrials.gov with EpicentRx, Inc. as lead sponsor.

NCT NCT04673942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04673942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adapted Phase 2a/2b, Study to Evaluate the Safety, Tolerability, and Efficacy of AdAPT-001 in Subjects With Refractory Solid Tumors
Lead sponsor
EpicentRx, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 29, 2021
Completion date
March 1, 2027
Enrollment
140 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, chondrosarcoma, neoplasms, sarcoma, sarcoma,soft tissue, solid tumor, adult